ARTICLE | Product Development
Singapore biotech aiming to overcome drug resistance by creating therapies carrying multiple payloads with orthogonal MoAs
By Danielle Golovin, Senior Biopharma Analyst
May 23, 2024 10:56 PM UTC
The ascendancy of antibody-drug conjugates as a therapeutic modality with broad utility in cancer has also revealed a major limitation of the tech — tumors often develop resistance to ADCs, leading to cancer progression.
The lightning-fast diversification of ADCs currently underway has put forward possible solutions, such as immune-stimulatory payloads meant to trigger a long-lasting antitumor immune response. The challenge with those approaches is to constrain the toxicity that results when the payload is released outside the tumor. …
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/652487/hummingbird-s-dual-adc-payloads-deliver-one-two-punch-to-tumors